Application No.	Applicant(s)		
09/827 846	EDA ET AL	FDA FT AI	
Examiner	Art Unit		
Gailene R. Gabel	1641		
ppears on the cover sheet wit IS (OR REMAINS) CLOSED in 85) or other appropriate commu	th the correspondence ad this application. If not including a policy in the mailed in displaying	uded Je course THIS	
led 6/22/04.			
; now renumbered as claims 1-	10, respectively.		
by the Examiner.			
ave been received. ave been received in Application	n No. <u>09/129,744</u> .	cation from the	
E" of this communication to file NMENT of this application.	a reply complying with the r	requirements	
omitted. Note the attached EXA lives reason(s) why the oath or	MINER'S AMENDMENT or declaration is deficient.	NOTICE OF	
erson's Patent Drawing Review er's Amendment / Comment or i R 1.84(c)) should be written on the n the header according to 37 CFR posit of BIOLOGICAL MATE	n the Office action of drawings in the front (not the 1.1.121(d). RIAL must be submitted.	•	
6. 🖾 Interview Sur Paper No./M 7. 🗆 Examiner's A 8. 🖾 Examiner's S 9. 🗀 Other	nmary (PTO-413), lail Date <u>8/11/04</u> . mendment/Comment		
	D9/827,846 Examiner Gailene R. Gabel Ppears on the cover sheet with SIS (OR REMAINS) CLOSED in 85) or other appropriate community of RIGHTS. This application is signed 6/22/04. Right and MPEP 1308. Right and MPEP 130	D9/827,846 Examiner Gailene R. Gabel Ppears on the cover sheet with the correspondence ad IS (OR REMAINS) CLOSED in this application. If not incl 85 or other appropriate communication will be mailed in dir RIGHTS. This application is subject to withdrawal from is 313 and MPEP 1308. It now renumbered as claims 1-10, respectively. by the Examiner. y under 35 U.S.C. § 119(a)-(d) or (f). ave been received. ave been received in Application No. 09/129,744. documents have been received in this national stage application. E" of this communication to file a reply complying with the information of the disciplinary of the submitted. Note the attached EXAMINER'S AMENDMENT or gives reason(s) why the oath or declaration is deficient. Insust be submitted. erson's Patent Drawing Review (PTO-948) attached er's Amendment / Comment or in the Office action of R 1.84(c)) should be written on the drawings in the front (not the national stage) application of BIOLOGICAL MATERIAL must be submitted. 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 5. □ Notice of Informal Patent Application (P' A) 6. □ Interview Summary (PTO-413), 7. □ Examiner's Statement of Reasons for All 9. □ Other □	

Application/Control Number: 09/827,846

Art Unit: 1641

REASONS FOR ALLOWANCE

Page 2

- 1. The following is an examiner's statement of reasons for allowance: The prior art of record does not teach or fairly suggest an agglutination assay reagent comprising a binary population of microparticles having a mean diameter size of 30 nm to 600 nm and capable of causing light scattering a wavelengths between 300 and 1200 nm, and wherein the first population of microparticles have a greater mean diameter, greater refractive index, stronger light scattering properties, and have a binding partner with a higher reactivity for an analyte than the binding partner for the analyte coated upon the corresponding second population of microparticles. Lindmo et al., cited for teaching a reagent comprising a binary mixture of microparticles in flow cytometry, does not teach or suggest a mean diameter of 30 nm to 600 nm for the microparticles for each population of microparticles. Grange et al., cited for teaching an agglutination reagent comprising 300 nm mean diameter of microparticles does not teach or suggest binary populations of microparticles in the reagent for use in an agglutination assay.
- 2. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 09/827,846

Art Unit: 1641

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gailene R. Gabel whose telephone number is (571) 272-0820. The examiner can normally be reached on Monday, Tuesday, and Thursday, 7:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gailene R. Gabel Patent Examiner Art Unit 1641 August 11, 2004

38

CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP 1800-7647

8/11/8

Christyn L. Chin